Trial reportBMC anesthesiology2026
Effective doses of remimazolam for sedation in paediatric magnetic resonance imaging following dexmedetomidine premedication: a dose-finding study.
Trial report in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Feasibility of remimazolam rescue sedation for neonatal MRI: a case report.BMC anesthesiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEffective sedation for paediatric magnetic resonance imaging (MRI) requires balancing depth control and safety. This dose-finding study aims to establish the 50% (ED50) and 90% (ED90) effective doses of intravenous remimazolam following intranasal dexmedetomidine premedication to optimise this sequential regimen.
methodsIn this single-centre trial (March-December 2024), children aged 3 months to 6 years requiring MRI sedation were enrolled. After intranasal dexmedetomidine (3 µg·kg⁻¹), children adequately sedated by dexmedetomidine alone were excluded. 150 children with inadequate sedation were stratified by age (3–12 months, 1–3 years, 3–6 years) and administered remimazolam via Dixon’s up-and-down method. ED50 and ED90 with 95%CI were calculated via probit regression. Vital signs, adverse events, awake time, and post-sedation side effects were recorded.
resultsRemimazolam for successful sedation maintained consistent ED50 values of 0.12 mg·kg− 1 across all paediatric age groups. ED90 values slightly increased from 0.20 mg·kg− 1 in infants and toddlers to 0.23 mg·kg− 1 in preschoolers. MRI was successfully completed in 93.3% of patients, while 6.7% required additional medication during the examination. Adverse events occurred in 15.3% of children, including transient hypotension in 2%, bradycardia in 0.7%, and hypoxia in 0.7%; all events were self-limiting without intervention.
conclusionsThis prospective study defines the ED50 and ED90 of remimazolam following dexmedetomidine premedication in dexmedetomidine-non-responders for paediatric MRI sedation. The sequential regimen demonstrated consistent weight-based dosing requirements with a favorable safety profile.
trial registrationThe trial was prospectively registered in the Chinese Clinical Trial Registry (chictr.org.cn; No. ChiCTR2400081218) on February 26, 2024.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.